First steps towards a new approach to epilepsy treatment

Jun 19, 2008

The most prestigious funding body in the world for epilepsy has financially backed Australian research into new approaches to treat the condition.

The Epilepsy Therapy Project will provide almost US$300,000 over the next two years to a group of researchers from leading Australian institutions including the University of Newcastle.

The group will further develop new ways to treat the one-third of epilepsy patients for whom current treatments do not control their seizures.

Associate Professor Adam McCluskey from the University's School of Environmental andLife Sciences said the new funding would build on recent discoveries involving brain cell communication in sufferers of epilepsy.

"We have already found that compounds designed to block the action of a protein calleddynamin are effective against laboratory models of epilepsy – in these models they appear to block progression of key elements associated with epileptic seizures," Associate Professor McCluskey said.

"Four classes of drugs have been tested and two of these show real potential in stopping epileptic seizures, which is promising news for the one-third of people who don't respond to current treatments."

Approximately one in 120 people have epilepsy, while up to five per cent of the world's population will have a seizure at some time in their lives.

"The funding will allow us to continue clinical development of the new drugs and move towards commercialisation. If all goes to plan a new treatment for epilepsy could beentering clinical trials within the next three to five years," Associate Professor McCluskey said.

Source: Research Australia

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.